T1	Participants 81 99	patients with AIDS
T2	Participants 226 281	patients with acquired immunodeficiency syndrome (AIDS)
T3	Participants 586 679	165-microg/injection [35 eyes, 30 patients] and 330-microg/injection [153 eyes, 120 patients]
